Life sciences news

Featured image of the article Sofi-cel (WU-CART-007): A CRISPR-Edited, Off-the-Shelf Anti-CD7 CAR-T Advancing Through FDA Expedited Pathways.

Sofi-cel (WU-CART-007): A CRISPR-Edited, Off-the-Shelf Anti-CD7 CAR-T Advancing Through FDA Expedited Pathways

Posted on by

SOPHIA ANTIPOLIS, France – March 2nd, 2026 │ Wugen has received Breakthrough Therapy Designation from the U.S. FDA for its investigational CAR-T cell therapy, Sofi-cel, for patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL). In these cancers, relapses remain a major challenge. These aggressive T-cell malignancies[…]

Featured image of the article Roche Secures Exclusive Rights to MediLink’s YL201, a B7-H3 ADC Against Solid Tumors.

Roche Secures Exclusive Rights to MediLink’s YL201, a B7-H3 ADC Against Solid Tumors

Posted on by

SOPHIA ANTIPOLIS, France – January 30, 2026 │ Roche’s new $570M near‑term licensing deal for MediLink’s YL201 underscores the strategic premium placed on differentiated ADC assets—and on the IP required to defend them. Roche announced an exclusive licensing agreement with China’s MediLink Therapeutics for YL201, an investigational antibody–drug conjugate (ADC) targeting B7-H3 (CD276). Roche will[…]

Featured image of the article Postbiotics in dermatological skincare: from microbiome science to intellectual property strategies.

Postbiotics in dermatological skincare: from microbiome science to intellectual property strategies

Posted on by

SOPHIA ANTIPOLIS, France – January 28, 2026 │ The growing understanding of the skin microbiome has profoundly reshaped approaches to dermatological and dermocosmetic innovation. Among emerging strategies, postbiotics, defined as non-living bacterial derivatives with biological activity, are gaining increasing attention as safe and stable alternatives to live probiotics. Positioned as the crossroads of immunology, skin[…]

Featured image of the article Emerging Therapeutic mRNA Innovators Revealed by Patent Monitoring: A PopVax IP Analysis.

Emerging Therapeutic mRNA Innovators Revealed by Patent Monitoring: A PopVax IP Analysis

Posted on by

SOPHIA ANTIPOLIS, France – January 16, 2026 │ This quarter, KnowMade’s Therapeutic mRNA patent monitoring service highlights PopVax as an emerging innovator driving multivalent mRNA vaccines and next-generation delivery platforms. Identifying Emerging mRNA Innovators Through Patent Surveillance: The Case of PopVax Patent Monitoring as a Strategic Lens on Therapeutic mRNA Innovation Patent monitoring has become[…]